Literature DB >> 17090657

CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins.

Elaine M Sloand1, Loretta Pfannes, Gubin Chen, Simant Shah, Elena E Solomou, John Barrett, Neal S Young.   

Abstract

CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) are distinguished from other MDS cells and from normal hematopoietic cells by their pronounced expression of apoptotic markers. Paradoxically, trisomy 8 clones can persist in patients with bone marrow failure and expand following immunosuppression. We previously demonstrated up-regulation of c-myc and CD1 by microarray analysis. Here, we confirmed these findings by real-time polymerase chain reaction (PCR), demonstrated up-regulation of survivin, c-myc, and CD1 protein expression, and documented comparable colony formation by annexin(+) trisomy 8(-) CD34(+) and annexin(-) CD34 cells. There were low levels of DNA degradation in annexin(+) trisomy 8 CD34 cells, which were comparable with annexin(-) CD34 cells. Trisomy 8 cells were resistant to apoptosis induced by gamma irradiation. Knock-down of survivin by siRNA resulted in preferential loss of trisomy 8 cells. These results suggest that trisomy 8 cells undergo incomplete apoptosis and are nonetheless capable of colony formation and growth.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17090657      PMCID: PMC1852203          DOI: 10.1182/blood-2006-01-030643

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  33 in total

Review 1.  Cell death inhibition: keeping caspases in check.

Authors:  L Goyal
Journal:  Cell       Date:  2001-03-23       Impact factor: 41.582

2.  Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells.

Authors:  E M Sloand; J Maciejewski; P Kumar; S Kim; A Chaudhuri; N Young
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

3.  T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia.

Authors:  Elena E Solomou; Keyvan Keyvanfar; Neal S Young
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

4.  Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival.

Authors:  P J Ho; R D Brown; G J Pelka; A Basten; J Gibson; D E Joshua
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

5.  Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics.

Authors:  K Virtaneva; F A Wright; S M Tanner; B Yuan; W J Lemon; M A Caligiuri; C D Bloomfield; A de La Chapelle ; R Krahe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

6.  c-Myc enhances protein synthesis and cell size during B lymphocyte development.

Authors:  B M Iritani; R N Eisenman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

Review 7.  Apoptosis and the systolic dysfunction in congestive heart failure. Story of apoptosis interruptus and zombie myocytes.

Authors:  J Narula; E Arbustini; Y Chandrashekhar; M Schwaiger
Journal:  Cardiol Clin       Date:  2001-02       Impact factor: 2.213

8.  Disturbed expression of the anti-apoptosis gene, survivin, and EPR-1 in hematological malignancies.

Authors:  I Shinozawa; K Inokuchi; I Wakabayashi; K Dan
Journal:  Leuk Res       Date:  2000-11       Impact factor: 3.156

9.  Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia.

Authors:  Jaroslaw P Maciejewski; Antonio Risitano; Elaine M Sloand; Olga Nunez; Neal S Young
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

10.  Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia.

Authors:  Elaine Sloand; Sonnie Kim; Jaroslaw P Maciejewski; John Tisdale; Dean Follmann; Neal S Young
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

View more
  29 in total

1.  Spontaneous abrogation of the G₂DNA damage checkpoint has clinical benefits but promotes leukemogenesis in Fanconi anemia patients.

Authors:  Raphael Ceccaldi; Delphine Briot; Jérôme Larghero; Nadia Vasquez; Catherine Dubois d'Enghien; Delphine Chamousset; Maria-Elena Noguera; Quinten Waisfisz; Olivier Hermine; Corinne Pondarre; Thierry Leblanc; Eliane Gluckman; Hans Joenje; Dominique Stoppa-Lyonnet; Gérard Socié; Jean Soulier
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

2.  T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.

Authors:  Elaine M Sloand; J Joseph Melenhorst; Zachary C G Tucker; Loretta Pfannes; Jason M Brenchley; Agnes Yong; Valeria Visconte; Colin Wu; Emma Gostick; Phillip Scheinberg; Matthew J Olnes; Daniel C Douek; David A Price; A John Barrett; Neal S Young
Journal:  Blood       Date:  2010-11-19       Impact factor: 22.113

Review 3.  Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.

Authors:  A John Barrett; Elaine Sloand
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

Review 4.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 5.  Molecular pathophysiology of myelodysplastic syndromes.

Authors:  R Coleman Lindsley; Benjamin L Ebert
Journal:  Annu Rev Pathol       Date:  2012-08-28       Impact factor: 23.472

6.  Effects of telomerase activity and apoptosis on ex vivo expansion of cord blood CD34(+) cells.

Authors:  J Ge; H Cai; Q Li; Z Du; W S Tan
Journal:  Cell Prolif       Date:  2012-12-15       Impact factor: 6.831

7.  Generalized eruptive histiocytomas and rosai-dorfman disease presenting concurrently in a patient with myelodysplastic syndrome.

Authors:  Benjamin Kaffenberger; Kamruz Darabi; Sara Peters; Sara Peters; Jessica Kynyk; Mark Bechtel
Journal:  J Clin Aesthet Dermatol       Date:  2012-08

8.  Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.

Authors:  Mahesh Seetharam; Alice C Fan; Mai Tran; Liwen Xu; John P Renschler; Dean W Felsher; Kunju Sridhar; Francois Wilhelm; Peter L Greenberg
Journal:  Leuk Res       Date:  2011-09-14       Impact factor: 3.156

9.  Pediatric intestinal Behçet disease complicated by myeloid malignancies.

Authors:  Kiichiro Kanamitsu; Akira Shimada; Ritsuo Nishiuchi; Tomonari Shigemura; Yozo Nakazawa; Kenichi Koike; Yuichi Kodama; Yuichi Shinkoda; Yoshifumi Kawano; Kozo Yasui; Koji Sasaki; Ryosuke Kajiwara; Hirokazu Tsukahara; Atsushi Manabe
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

Review 10.  MYC oncogene in myeloid neoplasias.

Authors:  M Dolores Delgado; Marta Albajar; M Teresa Gomez-Casares; Ana Batlle; Javier León
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.